v3.26.1
EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY
 6 Months Ended
Jun. 27, 2026
Earnings Per Share [Abstract]  
EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY
Earnings per Share

A reconciliation of the numerators and denominators used in our basic and diluted earnings per share (“EPS”) calculation is as follows (in millions):
Three Months EndedSix Months Ended
June 27, 2026June 28, 2025June 27, 2026June 28, 2025
Numerator:
Income (loss) from continuing operations$88.5 $(0.5)$(301.3)$(0.4)
Loss from discontinued operations, net of tax(14.1)(7.9)(22.8)(14.4)
Net income (loss)$74.5 $(8.4)$(324.1)$(14.8)
Denominator:
Weighted average shares outstanding for basic EPS139.1 138.2 138.9 138.0 
Dilutive effect of share-based awards(1)
0.6 — — — 
Weighted average shares outstanding for diluted EPS139.6 138.2 138.9 138.0 
(1) In the period of a net loss, diluted shares equal basic shares.

Shareholders' Equity

Our common stock consists of ordinary shares of Perrigo Company plc, a public limited company incorporated under the laws of Ireland.
    
Our common equity has traded on the New York Stock Exchange under the symbol PRGO since June 6, 2013. Prior to that, our common equity traded on the Nasdaq Global Select Market under the same symbol. Our common equity was also traded on the Tel Aviv Stock Exchange (“TASE”) under the same symbol between March 16, 2005 and February 23, 2022, when we voluntarily delisted from trading in connection with the Rx business divestiture.